A Comprehensive Review: The Evolution of Animal Models in Pulmonary Hypertension Research; Are We there Yet?

Citations Over TimeTop 10% of 2013 papers

Abstract

Pulmonary hypertension (PH) is a disorder that develops as a result of remodeling of the pulmonary vasculature and is characterized by narrowing/obliteration of small pulmonary arteries, leading to increased mean pulmonary artery pressure and pulmonary vascular resistance. Subsequently, PH increases the right ventricular afterload, which leads to right ventricular hypertrophy and eventually right ventricular failure. The pathophysiology of PH is not fully elucidated, and current treatments have only a modest impact on patient survival and quality of life. Thus, there is an urgent need for improved treatments or a cure. The use of animal models has contributed extensively to the current understanding of PH pathophysiology and the investigation of experimental treatments. However, PH in current animal models may not fully represent current clinical observations. For example, PH in animal models appears to be curable with many therapeutic interventions, and the severity of PH in animal models is also believed to correlate poorly with that observed in humans. In this review, we discuss a variety of animal models in PH research, some of their contributions to the field, their shortcomings, and how these have been addressed. We highlight the fact that the constant development and evolution of animal models will help us to more closely model the severity and heterogeneity of PH observed in humans.

Related Papers

• → Accuracy of doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates(2000)210 cited
• → Pharmacological Manipulation of Peripheral Vascular Resistance in Single Ventricle Patients (Stages I, II, and III of Palliation)(2015)3 cited
• [Determination of pulmonary vascular resistance by improved right heart catheter in rat].(2011)
• Effect of Feixinping on ET and NOSmRNA Expression in Pulmonary Artery in Rats with Pulmonary Hypertension in Pulmonary Heart Disease(2009)
• → Computed tomography measurement of pulmonary artery size in interstitial lung disease to evaluate pulmonary hypertension(2022)